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Aims Coronary artery disease is the leading cause of death in western countries, and its association with lower extremity
peripheral artery disease (LE-PAD) represents an independent predictor of worse outcome. However, the molecular
mechanisms underlying these effects are currently unknown.
Methods
and results
To investigate these processes, we used in vitro approaches and several mouse models: (i) unilateral limb ischaemia by
left common femoral artery ligation [peripheral ischaemia (PI), n ¼ 38]; (ii) myocardial infarction by permanent ligation
of the left descending coronary artery (MI, n ¼ 40); (iii) MI after 5 weeks of limb ischaemia (PI + MI, n ¼ 44); (iv) sham
operation (SHAM, n ¼ 20). Compared with MI, PI + MI hearts were characterized by a significant increase in cardio-
myocyte apoptosis, larger infarct areas, and decreased cardiac function. By using a proteomic approach, we identified a
8 kDa circulating peptide, Dermcidin (DCD), secreted by ischaemic skeletal muscles, enhancing cardiomyocytes
apoptosis under hypoxic conditions and infarct size after permanent coronary artery ligation. siRNA interference ex-
periments to reduce DCD circulating levels significantly reduced infarct size and ameliorated cardiac function after MI.
Conclusion Our data demonstrate that chronic limb ischaemia activates detrimental pathways in the ischaemic heart through
humoral mechanisms of remote organ crosstalk. Thus, DCD may represent a novel important myokine modulating
cardiomyocyte survival and function.
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1. Introduction
Coronary artery disease (CAD) is an important clinical manifestation
of systemic atherosclerosis and represents the first cause of death in
industrialized countries.1 In CAD patients, abrupt coronary occlusion
determines a permanent loss of cardiac myocytes, and infarct size is
one of the major determinants of subsequent pathological cardiac
remodelling and heart failure.2 Experimental inhibition of programmed
cell death during the acute phase of myocardial ischaemia can reduce
the extension of the infarct area and, in turn, ameliorate post-ischaemic
cardiac dysfunction and prolong survival.2
In patients with established CAD, large clinical studies have previously
shown that the coexistence of lower extremity peripheral artery
disease (LE-PAD) causes a worsening of the clinical course and
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prognosis.3 In addition, LE-PAD patients were demonstrated to have a
three- to six-fold higher risk of cardiovascular events than those with
similar risk factors, but without lower extremity ischaemia.3,4 The in-
creased vulnerability to cardiovascular (CV) events in patients with
CAD can be partially explained by shared CV risk factors and excess
inflammation indicated by significantly higher serum levels of inflamma-
tory bio-markers in LE-PAD population.5,6 However, this assumption
has been recently challenged, since in patients with CAD, concomitant
LE-PAD does not necessarily entail a more severe coronary athero-
sclerosis,3 and only patients with an active inflammatory status of the
affected limb present severe CAD3 or coronary artery endothelial dys-
function.7 Thus, the mechanisms underlying these synergistic detrimen-
tal effects are currently unknown.
Previous observations have reported that skeletal muscle metabol-
ism can cause the local generation of cytokines that can be detected
in the serum and may exert either systemic and/or paracrine effects.8
Although muscle cells might not exclusively secrete these factors,
they are usually classified as ‘myokines’ within the context of skeletal
muscle physiology. Emerging evidence suggests that these muscle-
derived molecules play an important role in mediating both acute
metabolic changes, as well as the long-term metabolic regulatory
mechanisms in distant organs like the adipose tissue and liver.9
Thus, in the present study, we tested the hypothesis that ischaemic
skeletal muscles might produce and release into the bloodstream sol-
uble molecules exerting remote effects on cardiomyocyte survival/
functionality. To unveil the molecular signals involved in the crosstalk
between ischaemic skeletal muscles and the heart, we investigated
with proteomic procedures two well-established murine models of
cardiac and/or peripheral ischaemia (PI) induced by permanent coron-
ary and/or femoral arteries ligation. Here, we identify the skeletal
muscle-secreted peptide Dermcidin (DCD) as a novel molecular signal
underlying the remote crosstalk between the skeletal muscles and the
heart.
2. Methods
An expanded Methods section is given in the Supplementary material
online.
2.1 Animal studies
All experiments involving animals in this study conformed to the Guide
for the Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication 8th edition, update 2011), and were
approved by the animal welfare regulation of the University of Naples
Federico II, Italy. Details are provided in Supplementary material online.
2.2 Mouse model of myocardial infarction
Mice were anaesthetized with an intraperitoneal injection of 1 mL/kg
(50 mg/kg) of a mixture of 50% tiletamine and 50% zolazepam (50 mg/mL
tiletamine and 50 mg/mL zolazepam, Zoletil 100), plus xylazine 5 mg/kg
(Sigma-Aldrich). The adequacy of anaesthesia was confirmed by the absence
of reflex response to foot squeeze. Myocardial infarction (MI, n ¼ 40) was
induced in mice by permanent ligation of the left coronary artery, as previ-
ously described.10 Details are provided in Supplementary material online.
2.3 Mouse model of chronic hindlimb ischaemia
Hindlimb ischaemia (PI, n ¼ 38) was induced in mice as previously de-
scribed.11,12 Details are provided in Supplementary material online. After
5 weeks of hindlimb ischaemia, an additional group of PI mice underwent
myocardial infarction as described earlier (PI + MI, n ¼ 44).
2.4 Transthoracic echocardiography
Cardiac function was non-invasively monitored by transthoracic echocardi-
ography by using a Vevo 770 high-resolution imaging system (VisualSonics,
Toronto, Canada) before the surgery and right before termination, 7 days
after myocardial infarction as previously described.13 Details are provided
in Supplementary material online.
2.5 Measurement of blood pressure and cardiac
function
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
measured in conscious mice from different experimental groups using a
non-invasive computerized tail-cuff system (Visitech Systems, Apex, NC,
USA) as described previously.14,15 Details are provided in Supplementary
material online.
2.6 Morphological studies
Mouse heart specimens fixed in 4% formaldehyde were embedded in
paraffin; after de-paraffinization and re-hydratation, 4 mm-thick sections
were prepared, mounted on glass slides and stained with Haematoxylin–
Eosin, Sirius red, lectin, or Terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL). Details are provided in Supplementary material
online.
2.7 Cell cultures, in vitro hypoxia, and lactate
dehydrogenase measurement
Primary cultures of neonatal ventricular myocytes (NVMs) were prepared
from 1/3-day-old Wistar rats sacrificed by cervical dislocation followed by
decapitation, as previously described.16 NVMs were cultured in serum-free
conditions for 48 h before experiments, and then incubated with 1:50 dilu-
tion of serum from SHAM, PI, MI, and PI + MI animals, under normoxic or
hypoxic conditions (discussed subsequently), for 4 h. In additional experi-
ments, NVMs were incubated with the tagged fusion DCD peptide corre-
sponding to amino acids 20–110 (Santa Cruz Biotechnology) under
normoxic and hypoxic conditions. Details are provided in Supplementary
material online. Hypoxia (2% O2) was induced when NVMs were at 0.85
confluence. Details are provided in Supplementary material online. Lactate
dehydrogenase (LDH) levels in NVMs supernatants from different experi-
mental groups were determined by using LDH assay kit (Abcam) according
to the manufacturer’s instructions.
2.8 Immunodepletion assay
For immunodepletion experiments, serum samples from SHAM and PI
were incubated twice with a polyclonal rabbit antibody against DCD
(3 mg, Santa Cruz Biotechnology) or control IgG (3 mg, Santa Cruz Biotech-
nology) for 1 h, at 48C, and incubated with 20 mL of protein G-agarose
beads (GIBCO-BRL) on a roller system, for another 1 h, at 48C. Details
are provided in Supplementary material online.
2.9 Annexin V and propidium iodide staining
Cultured cells were rinsed with ice-cold phosphate-buffered saline (PBS),
fixed with 3.7% formaldehyde in PBS for 30 min, permeabilized with 0.2%
Triton X-100 in PBS, and then incubated with 2% bovine serum albumin in
PBS for 1 h, at room temperature. In order to evaluate apoptotic cell death,
cultured cells were stained with Annexin V Cy3 (MBL, Japan) and propi-
dium iodide (P) (Sigma-Aldrich), and the percentage of apoptosis was ana-
lysed by fluorescence microscopy or by flow cytometry (Epics XL,
Beckman Coulter). Further details are provided in Supplementary material
online.
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2.10 Protein extraction, immunoblot analysis,
immunohistochemistry, and
immunofluorescence
Cultured cells and left-ventricular samples were lysed and immunoblotting
was performed by using commercially available antibodies anti-DCD (rab-
bit polyclonal, Santa Cruz), PARP (mouse monoclonal, Santa Cruz),
Caspase-3 (rabbit polyclonal, Cell Signaling), cleaved Caspase-3 (rabbit
polyclonal, Cell Signaling) a-heavy chain myosin (a-MHC, mouse monoclo-
nal, Abcam), and GAPDH (mouse monoclonal, Upstate Biotechnology).
a-MHC immunostaining were performed on 4 mm-thick deparaffinized
and rehydrated through decreasing ethanol concentrations heart sections.
Details are provided in Supplementary material online.
2.11 Bio-plex cytokines assay
Tumour necrosis factor a (TNF-a), Interleukin 1b (IL-1b) and Interleukin 6
(IL-6) activation was evaluated in sera from SHAM, MI, and PI mice by
Bio-Plex cytokine assay (Bio-Rad) according to the manufacturer’s instruc-
tions and as previously described.17
2.12 Serum fractionation and mass
spectrometric analysis
Sera from SHAM and PI mice were subjected to subfractionation by using
10 kDa Spin Column devices (Amicon, Millipore) to isolate a protein sub-
fraction with components having molecular mass ,10 kDa (SHAM ,
10 kDa or PI, 10 kDa) or a protein subfraction with components having
molecular mass .10 kDa (SHAM . 10 kDa or PI . 10 kDa). Next, sera
SHAM , 10 kDa or PI , 10 kDa were subjected to high-pressure liquid
chromatography (HPLC) fractionation on a C18 Jupiter column (250 ×
2.1 mm, 5 mm Phenomenex) eluted with a linear gradient (from 5 to
75%) of 0.1% trifluoroacetic acid, acetonitrile in 0.1% trifluoroacetic acid
over 70 min, at a flow rate 0.2 mL/min. After sample injection, fraction col-
lection was set up to continuously accumulate portions of 0.4 mL each,
which were then lyophilized and further subjected to the apoptotic assays
reported earlier and/or to MS analysis. Details are provided in Supplemen-
tary material online.
2.13 RNA extraction, cDNA synthesis,
real-time PCR, and sequence alignment
Total RNA was prepared by using the TRIzol procedure (Invitrogen, Eu-
gene, OR, USA), according to the manufacturer’s instruction. Oligo-dT first
strands cDNAwere synthesized using the SuperScript VILO cDNA Synthe-
sis (Invitrogen, Life technologies) according to the manufacturer’s
instructions.
DCDmRNA expression was determined in cardiac and skeletal muscles
by quantitative real-time PCR (RT-PCR) using a IQ-5 Multicolor Real-Time
PCR detection system (Bio-Rad). The primers used are listed in Table 1. The
initial denaturation phase was performed at 958C for 5 min, followed by an
amplification phase as detailed in what follows: denaturation at 958C for
10 s; annealing at 608C for 30 s; elongation at 728C for 30 s; detection at
728C for 40 cycles.
DCD amino acid and cDNA sequences were obtained by sequence
service at CEINGE-Advanced Biotechnology, Federico II University,
Naples, Italy and alignment were performed by the web-accessible
ClustalW2 tool.
2.14 siRNA studies
DCD expression knockdown in mice was obtained by using a
small-interfering RNA (siRNA) synthesized by Santa Cruz (siDCD).
Forty-eight hours before coronary artery ligation, siDCD (30 nmol/kg) or
negative, fluorescein isothiocyanate (FITC)-conjugated control siRNA
(siCTR) (660 mmol/mouse) (Santa Cruz) diluted in PBS were injected in
PI + MI mice via the tail vein (PI + MI siDCD, n ¼ 10 and PI + MI siCTR,
n ¼ 6), as previously described.18 Efficacy of siRNA approachwas evaluated
by visualizing FITC-expression in the skeletal muscle sections by green
fluorescence.
2.15 Statistical analysis
All data are reported as mean+ SEM. Comparisons between two groups
were performed using the unpaired Student’s t-test. For four groups
experiments, comparisons were made by two-way analysis of variance
(ANOVA). Correction for multiple comparisons was made using the
Student–Newman–Keuls method. A P-value of ,0.05 was considered
statistically significant. All the analyses were performed with the GraphPad
Prism version 5.01 (GraphPad Software, San Diego, CA, USA).
3. Results
3.1 Chronic hindlimb ischaemia enhances
apoptotic cardiomyocyte death and
increases infarct size after coronary artery
ligation in mice
To address themolecular mechanisms underlying the possible interplay
between limbs and cardiac ischaemia in vivo, two murine models of car-
diac or PI were used. To induce chronic limb ischaemia, C57BL/6 mice
(n ¼ 82) underwent 5 weeks of femoral artery ligation (PI), as previous-
ly described.11,12 In some PI mice (n ¼ 44), after 5 weeks of hindlimb
ischaemia, myocardial infarction was induced by permanent coronary
artery ligation (PI + MI) as previously described.10 In an additional
group of mice (n ¼ 40), only coronary artery ligation was performed
(MI). SHAM-operated animals (n ¼ 20) underwent the same surgical
procedures without ligation of the femoral or coronary arteries.
Twenty-four hours following permanent coronary artery ligation, MI
or PI + MI hearts (n ¼ 7 and n ¼ 8, respectively) were infused with
Evans blue to demarcate the ischaemic area susceptible to infarction
[area at risk (AAR)], and counterstained with triphenyltetrazolium
chloride to identify the infarct area (IA) from the viable myocardium
within the AAR. Despite similar AARs between the two MI groups (Ta-
ble 2), PI + MI hearts demonstrated a significantly larger proportion of
infarcted myocardium within the AAR, when compared with MI mice
(Table 2 and Figure 1A). Seven days after coronary artery ligation,
PI + MI hearts still displayed a significantly larger infarct size by Sirius
red staining compared with MI (Figure 1B), suggesting that chronic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 DNA primers used in the study
GENE Forward Reverse
DCD 5′-GTTAGCCAGACAGGCACCA-3′ 5′-CTCCGTCTAGGCCTTTTTCC-3′
GAPDH 5′-TGCAGTGGCAAAGTGGAGATT-3′ 5′-TCGCTCCTGGAAGATGGTGAT-3′
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hindlimb ischaemia at the time of coronary artery occlusion might en-
hance the detrimental actions of cardiac ischaemia.
Next, to evaluate the effects of these different conditions on cardiac
function, transthoracic echocardiography was performed in the
different groups (Figure 1C). As expected, while coronary artery ligation
produced myocardial infarction and a significant reduction of cardiac
function, chronic limb ischaemia did not affect cardiac function under
normal conditions (Figure 1C and Table 3). Interestingly, compared
with MI, PI + MI mice displayed a significant worsening in cardiac func-
tion after coronary artery ligation, and a more pronounced increase in
the left-ventricular weight (LVW) to body weight (BW) ratio at study
termination without a significant increase in end-diastolic wall thick-
nesses of either the interventricular septum (IVSd) or the posterior
wall (PW), consistent with an expansion of the infarct region and/or in-
creased oedema in the remote region (Table 3). These data suggest that
the contemporary presence of skeletal muscle ischaemia might aggra-
vate cardiac response to coronary artery occlusion. Moreover, there
was no significant change in systolic blood pressure (SBP), diastolic
blood pressure (DBP) or heart rate (HR) in either MI or MI + PI groups
(MI (mmHg): SBP ¼ 132.7+ 8.6, DBP ¼ 85.3+ 22.1; PI + MI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Infarct area and area at risk 24 h after permanent
coronary artery ligation in mice from the different
experimental groups
MI (n5 7) PI1MI (n5 8)
IA/AAR (%) 44.8+1.2 68.4+3.0*
AAR/LV (%) 32.3+1.3 31.4+1.5
IA, infarct area; AAR, area at risk; LV, left-ventricle area.
*P, 0.05 vs. MI.
Figure 1 Cardiac evaluation of mice with chronic hindlimb ischaemia and myocardial infarction. (A) Left: Representative images of triphenyltetrazolium
chloride (TTC) staining of cardiac sections from mice undergoing 24 h of permanent coronary artery ligation alone (MI) or 5 weeks of femoral artery
ligation to induce peripheral ischaemia (PI) followed by 24-h-MI (PI + MI) (scale bar ¼ 1 mm). Right: bar graphs showing ratios of myocardial infarct area
(IA) and area at risk (AAR) in MI and PI + MI groups (*P, 0.05 vs. MI; n ¼ 9 hearts/group). (B) Left: representative images of Sirius red staining of cardiac
sections after 7 days of permanent coronary artery ligation alone (MI) or 5 weeks of PI followed by 7-day-MI (PI + MI) (scale bar ¼ 2 mm). Right: bar
graphs showing percent infarct size in MI and PI + MI mice (*P, 0.05 vs. MI; n ¼ 10 hearts/group). (C) Left: representative M-mode echocardiographic
tracings. Right: cumulative data of % fractional shortening in MI, PI, PI + MI, or SHAMmice (*P, 0.05 vs. SHAM; **P, 0.05 vs. all; n ¼ 10 hearts/group).
(D) Left: representative lectin staining of cardiac sections from SHAM, MI, PI, and PI + MI mice. Capillaries appear brown (scale bar ¼ 500 nm). Right:
cumulative data of multiple independent experiments analyzing capillary density in the different groups (*P, 0.05 vs. SHAM and PI; n ¼ 7–8 hearts/
group). (E) Left: representative DAPI and TUNEL staining of cardiac sections from SHAM, MI, PI, and PI + MI mice. TUNEL-positive nuclei appear green
(scale bar ¼ 250 nm). Right: cumulative data of multiple independent experiments (*P, 0.05 vs. SHAM and PI; **P, 0.05 vs. all, n ¼ 7–8 hearts/group).
Experiments were repeated three times and the data pooled.
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(mmHg): SBP ¼ 139.4+ 12.6, DBP ¼ 103.2+ 11.6, not significant,
n ¼ 6 and n ¼ 8, respectively).
To rule out whether abnormal vascular density might be respon-
sible for the increased infarct size in PI + MI mice, histological studies
were performed in the infarct zone to stain cardiac capillaries in all
experimental groups. Notably, PI mice displayed a cardiac capillary
density similar to SHAM mice (Figure 1D), suggesting that hindlimb is-
chaemia may not affect microvascular remodelling in the normal
heart. As expected, coronary artery ligation induced a significant
reduction in myocardial capillary density (Figure 1D). Importantly,
when myocardial infarction was surgically induced after 5 weeks of
femoral artery ligation (PI + MI mice), vascular rarefaction was simi-
larly observed, supporting the concept that the differences observed
in PI + MI mice might not be attributed to alterations in the
microvasculature.
To assess whether increased apoptotic cell death might be involved
in the increased infarct size observed in PI + MI mice, terminal deoxy-
nucleotidyl transferase dUTP nick end labelling (TUNEL) staining was
performed in cardiac sections from the different groups. Compared
with MI, PI + MI hearts exhibited a significant increase in the rate of
TUNEL-positive nuclei in the infarct zone (Figure 1E). Importantly,
the vast majority of TUNEL-positive nuclei were localized within cardi-
omyocytes as shown in the Supplementary material online, Figure S1.
Taken together, these results suggest that hindlimb ischaemia enhances
cardiomyocyte apoptotic cell death induced by coronary artery liga-
tion. Importantly, MI and MI + PI hearts displayed a significant increase
in leucocytes infiltration in border zone of infarct. Conversely, SHAM
and PI hearts showed no significant infiltration (Supplementary material
online, Figure S2A). These data are consistent with the results that 5
weeks of limb ischaemia did not significantly affect the levels of the
pro-inflammatory cytokines TNF-a, IL-1b, and IL-6 (Supplementary
material online, Figure S2B), indicating that systemic inflammation might
not be directly involved in these processes.
3.2 Proteomic analysis and identification of
DCD as the pro-apoptotic factor in PI sera
To determine whether a secreted, circulating factor might be respon-
sible for the detrimental cardiac effects observed in PI + MI mice, rat
NVMs were incubated with equal parts of serum of mice from all ex-
perimental groups during normoxia or 4 h of hypoxia; then, apoptotic
cell death was evaluated by Annexin V staining. While no significant dif-
ferences were observed in normoxic conditions, hypoxic cardiomyo-
cytes incubated with either PI or PI + MI sera exhibited a significant
increase in Annexin V staining, compared with hypoxic cardiomyocytes
treated with SHAM or MI sera (Figure 2A).
In order to determine whether chronic limb ischaemia may promote
the systemic release of a circulating pro-apoptotic factor, sera from PI
mice were separated by ultrafiltration in two fractions, containing poly-
peptide molecules having a molecular mass higher or lower than 10 kDa
(PI . 10 kDa and PI, 10 kDa, respectively). The ability of both frac-
tions to induce apoptotic cell death was next tested in hypoxic or nor-
moxic cardiomyocytes (Figure 2B). Interestingly, only the PI, 10 kDa
fraction significantly induced apoptosis in hypoxic cardiomyocytes simi-
lar to the whole PI serum (Figure 2B, panels 23, 25). Thus, an HPLC sep-
aration step was applied to the PI , 10 kDa fraction to purify the
bioactive component responsible for the observed phenomenon (Sup-
plementary material online, Figure S3A). Collected subfractions were
tested in cardiomyocytes under normoxic or hypoxic conditions as pre-
viously described, and their apoptotic activity was evaluated by Annexin
V staining. Based on this assay, only adjacent subfractions #33 and #34
were found to promote apoptotic cell death in hypoxic cardiomyocytes
(Supplementarymaterial online, Figure S3B and Figure 2B, panels 26–28).
These fractions were further characterized byMALDI-TOF-MS analysis,
as previously described,19 and showed in both cases the presence of a
single component with a molecular mass of about 8601 kDa (Supple-
mentary material online, Figure 3C). This purified compound was further
digested with trypsin and characterized for its nature by nanoLC-
ESI-LIT-MS/MS as DCD (Supplementary material online, Figure 3D).
These experiments demonstrated the unique occurrence of three
mouse peptides in these fraction digests, namely LGKDAVEDLESVGK,
DAVEDLESVGK, and ENAGEDPGLAR, which are identical to the se-
quence of the corresponding human DCD protein (Supplementary
material online, Figure S3D). Next, to confirm DCD expression in mur-
ine skeletal muscles, we generated and sequenced DCD cDNA from
RNA. Interestingly, DCD cDNA mouse sequence showed 100%
homology to the human DCD mRNA (Supplementary material online,
Figure S4). The presence of DCD in the sera of PI mice and in the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Morphometric and echocardiographic evaluation
SHAM (n 5 20) PI (n 5 38) MI (n5 40) PI 1MI (n 5 44)
BW (g) 26.8+0.2 26.5+0.2 26.7+1.7 25.1+0.4
LVW (mg) 100.1+5.7 99.2+5.7 144.1+5.1* 162.4+14.3†
LVW/BW (mg/g) 3.7+0.1 3.7+0.1 5.3+0.2* 6.4+0.5†
LVEDD (mm) 3.2+0.04 3.1+0.03 3.4+0.11* 3.8+0.19*
LVESD (mm) 1.3+0.04 1.2+0.02 1.7+0.14* 2.4+0.31†
FS (%) 59.4+0.73 61.3+1.65 48.6+0.83* 36.7+1.87†
IVSd (mm) 0.9+0.03 0.9+0.12 1.0+0.05 1.1+0.12
PWd (mm) 0.8+0.02 0.8+0.32 0.9+0.04 0.9+0.03
HR (bpm) 533+13.35 528+13.35 543+27.28 527+26.12
SHAM, sham-operated control mice; MI, myocardial infarction; BW, body weight; LVW, left-ventricular weight; LVEDD, left-ventricular end-diastolic diameter; LVESD, left-ventricular
end-systolic diameter; FS, fractional shortening; IVSd, end-diastolic interventricular septum; PWd, end-diastolic posterior wall; HR, heart rate.
*P, 0.05 vs. SHAM.
†P, 0.05 vs. SHAM and MI.
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Figure 2 Proteomic identification of DCD as the pro-apoptotic factor in PI sera. (A) Left panels: Representative DAPI and Annexin V staining in rat
NVMs incubated with sera from SHAM, MI, PI, and PI + MI mice under normoxic or hypoxic conditions. Annexin V-positive cells appear green. Scale
bar ¼ 250 mm. Right panels: cumulative data of multiple independent experiments (*P, 0.05 vs. normoxia; **P, 0.05 vs. normoxia, SHAM, and MI
hypoxia; n ¼ 5). (B) Top: representative DAPI and Annexin V staining in NVMs under normoxic or hypoxic conditions incubated with sera from
SHAM or PI mice, .10 or ,10 kDa polypeptide components from PI sera, fractions #7, #33, and #34 separated by HPLC analysis from PI,10 kDa
sera. Annexin V-positive cells appear green. Scale bar ¼ 250 mm. Bottom: cumulative data of multiple independent experiments (*P, 0.05 vs. normoxia;
**P, 0.05 vs. all; n ¼ 5). (C) Representative immunoblot and densitometric analysis of four independent experiments to evaluate DCD protein levels in
SHAM, MI, PI, PI,10 kDa, PI.10 kDa sera (*P, 0.05 vs. all). GAPDH protein levels did not significantly change among the samples.
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corresponding PI , 10 kDa fraction was also confirmed by immuno-
blotting with a specific antibody (Figure 2C).
3.3 DCD induces apoptosis in hypoxic
cardiomyocytes
To test whether circulating plasma levels of DCD might exert detri-
mental effects on cardiomyocytes under normoxic or hypoxic condi-
tions, NVMs were grown in the presence of sera from PI mice
incubated with a specific DCD antibody (PI-DCD2) or with control
IgG (PI-DCD + ) (Figure 3A). Interestingly, while PI-DCD+ sera signifi-
cantly increased Annexin V staining of cardiomyocytes during hypoxia,
DCD immunodepletion significantly reduced these effects (Figure 3B).
To discriminate between apoptosis and necrosis of cardiomyocytes,
we performed double staining for P and Annexin V in isolated cardio-
myocytes treated with recombinant DCD peptide under normoxic and
hypoxic conditions. Interestingly, the % amount of P/annexin V staining
was increased in DCD-treated hypoxic neonatal cardiomyocytes com-
pared with hypoxic, untreated cardiomyocytes (Figure 3C). Moreover,
treatment with recombinant DCD increased lactic dehydrogenase ac-
tivity in hypoxic cardiomyocytes in the culture media (Figure 3D) and
caspase 3/poly(ADP-ribose) polymerase (PARP) cleavage (Figure 3E),
confirming the important role of DCD in the modulation of cell survival
of cardiomyocytes upon hypoxia.
3.4 DCD regulation in skeletal and cardiac
muscle
In order to assess DCD regulation in response to limb or cardiac is-
chaemia, expression analysis was performed on cardiac and limb mus-
cle samples from SHAM, MI, PI, and PI + MI mice. While DCD
expression in the heart was not affected by either coronary or femoral
artery ligation, DCD levels in skeletal muscles significantly increased
after femoral artery ligation and were unaffected by coronary artery li-
gation (Figure 4A). Consistent with these results, DCD mRNA levels
were significantly increased in ischaemic skeletal limbs (Figure 4B), while
they were unchanged in the hearts of mice undergoing femoral and/or
coronary artery ligation (Figure 4C). Taken together, these results indi-
cate that DCD is specifically induced in the skeletal muscle under is-
chaemic conditions.
3.5 In vivo DCD silencing reduces infarct
size in mice with chronic hindlimb ischaemia
In order to test whether the increase in DCD plasma levels might be
directly involved in cardiomyocyte survival during cardiac ischaemia,
an in vivo silencing approach was undertaken by systemically adminis-
tering small interfering RNA (siRNA) specific for DCD mRNA
(siDCD) in PI + MI mice. Control siRNAs conjugated with fluores-
cein isothiocyanate - FITC (siCTR) were also administered, and visua-
lized in limb skeletal muscles or cardiac sections by fluorescence
microscopy (Supplementary material online, Figure S5). As expected,
DCD mRNA and protein levels were significantly reduced in limb
muscles from PI + MI mice treated with siDCD (Figure 5A and B).
Strikingly, DCD silencing in mice with limb ischaemia significantly re-
duced the proportion of infarcted myocardium within the AAR after
coronary artery ligation [IA/AAR (%): PI + MI siCTR: 50.3+ 3.3; PI +
MI siDCD: 64.4+ 3.6; *P, 0.05, Figure 5C], suggesting that DCD le-
vels might modulate infarct size after 24 h of myocardial infarction in
mice with chronic limb ischaemia. Furthermore, transthoracic
echocardiography performed after 7 days of coronary artery ligation
showed that DCD silencing in mice with chronic limb ischaemia sig-
nificantly ameliorated cardiac dysfunction after myocardial infarction
(Figure 5D), suggesting that DCD circulating levels might modulate in-
farct size and post-ischaemic cardiac remodelling in mice with limb
and cardiac ischaemia.
4. Discussion
In this paper, we present data on a novel molecular mechanism under-
lying an inter-organ communication between skeletal muscles and the
heart, mediated by the muscle-secreted peptide DCD. After induction
of experimental limb ischaemia, DCD was released from skeletal mus-
cles in the systemic circulation, wherein it exerted critical effects on
cardiomyocyte survival during ischaemia, enhancing infarct size and
pathological cardiac remodelling after myocardial infarction. These re-
sults point at DCD as an important biomarker of skeletal muscle is-
chaemia, and a novel molecular target to ameliorate cardiac
maladaptive responses to ischaemia.
CAD is the single largest cause of death in developed countries, and
is one of the leading causes of disease burden in developing countries as
well.20 In subjects with known CAD, the simultaneous presence of any
kind of peripheral artery disease represents an independent and signifi-
cant predictor of death.3,4 While it is conceivable that the coexistence
of these two manifestations of atherosclerosis could be the expression,
at least in part, of a more severe systemic disease,5,6 the exceeding
morbidity and mortality for cardiovascular causes in these patients
has never been completely understood. Here we found that mice sub-
jected to chronic limb ischaemia had a worse outcome after myocardial
infarction, compared with animals undergoing myocardial infarction
alone. Notably, since these mouse models are characterized by the
absence of vascular atherosclerosis,12 these results indicate that
the detrimental cardiac effects induced by PI are independent from
atherosclerosis.
It has been previously proposed that skeletal muscle secretes mole-
cules, termed ‘myokines’, that might affect neighbour or remote organs
through a variety of mechanisms.8 In particular, PI might be able to
induce the release of factors, such as TNF-a or similar cytokines
with cardiodepressant actions.21 However, in the present study, no dif-
ferences in the circulating levels of major inflammatory cytokines or
myocardial inflammatory infiltrate were observed between SHAM
and PI mice (Supplementary material online, Figure S2), suggesting
that inflammation might not be the prominent mediator of the remote
crosstalk between skeletal muscles and the heart.
Remarkably, a proteomic analysis of sera from animals subjected to
femoral artery ligation identified the specific peptide DCD as the cru-
cial factor responsible for induction of apoptosis in hypoxic cardiomyo-
cytes. DCDwas originally identified in 2001 as an antimicrobial peptide
with a broad spectrum of activity, constitutively expressed and se-
creted by sweat glands.22 Subsequently, DCD expression has been de-
monstrated in a wide spectrum of tissues and cell lines.23,24,25,26 While
there is now a large amount of data concerning the role of DCD in can-
cer, its effects in cardiovascular pathophysiology are much less defined.
Recent studies have demonstrated increased DCD serum levels in pa-
tients with acute coronary syndromes and arterial hypertension.27,28
The same authors have also shown that DCD can increase platelets ag-
gregation, suggesting a potential role of DCD in artery thrombosis.27,28
Here we found that DCD relapsed by ischaemic skeletal muscles in
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Figure 3 Cardiomyocyte apoptosis induced by DCD. (A) Top: representative immunoblot of four independent experiments to evaluate DCD protein
immunodepletion in PI sera. DCDIgG indicates serum immunodepleted with DCD antibody and IgG indicates serum immunodepleted with control
immunoglobulin. (B) Left panels: representative DAPI and Annexin V staining in rat NVMs under normoxic or hypoxic conditions incubated with
sera from SHAM mice, or from PI mice incubated with specific anti-DCD antibody (PI-DCD2) or non-specific IgG (PI-DCD + ). Annexin V-positive
nuclei appear green. Scale bar ¼ 250 mm. Right panels: cumulative data of four multiple independent experiments (*P, 0.05 vs. normoxia;
**P, 0.05 vs. normoxia and SHAM hypoxia; §P, 0.05 vs. all). Scale bar ¼ 250 mm. (C ) Double staining for Annexin V and P in NVMs incubated
with a synthetic DCD peptide (DCD 20–110) or a control peptide (CTR) under normoxic or hypoxic conditions (*P, 0.05 vs. normoxia;
**P, 0.05 vs. all). (D) Lactic dehydrogenase activity released by NVMs incubated with a synthetic DCD peptide (DCD 20–110) or a control peptide
(CTR) under normoxic or hypoxic conditions (*P,0.05 vs. normoxia; **P,0.05 vs. all). (E) Representative immunoblots (left panels) and cumulative
data (right panels) of three independent experiments to evaluate the levels of cleaved PolyADP-ribose polymerase (PARP), cleaved caspase 3 and
GAPDH in NVMs under normoxic or hypoxic conditions incubated with a synthetic DCD peptide (DCD 20–110) or a control peptide (CTR;
*P, 0.05 vs. normoxia; **P, 0.05 vs. all).
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the systemic circulation can enhance cardiomyocyte apoptosis and
adverse cardiac remodelling induced by myocardial infarction. Interest-
ingly, we never detected activation of the apoptotic cascade in nor-
moxic cardiomyocytes incubated with DCD, suggesting that this
peptide might have no direct toxic effects on these cells, but rather re-
presents a novel, circulating factor that sensitizes, with an unknown
mechanism, cardiomyocytes to an ischaemic insult. Consistently, the
systemic delivery of specific DCD siRNA determined a significantly
smaller infarct size area and a better cardiac function after coronary ar-
tery ligation, indicating DCD as a crucial factor in the modulation of car-
diomyocytes survival under hypoxic conditions in vitro and in vivo.
However, we cannot exclude that other important pathophysiological
mechanisms might also be involved in the development of pathological
remodelling and cardiac dysfunction under these experimental
conditions.
In contrast to our results indicating DCD’s detrimental effects on
cardiomyocytes and the whole heart, in several solid tumours DCD
has been demonstrated to induce cellular proliferation, migration,
and survival during hypoxia.29–31 However, DCD gene codes for a se-
creted precursor protein of 110 amino acid residues with a high sus-
ceptibility to proteolytic processing,32 and while we found a
full-length DCD protein in all our mass-spectrometry and proteomic
analyses, several DCD products have been shown to be processed
by neuronal cells or tumour cells. In particular, a peptide comprising
the first 30 amino acids of the DCD precursor protein named
Y-P30,33 and another 20-amino-acid peptide derived from the
N-terminal end of the DCD protein (proteolysis-inducing factor, PIF)
exhibit a different range of biological functions despite large homolo-
gies in the amino acid sequences.32 Whether DCD and/or its derived
peptides interact with different target receptors is currently not
Figure 4 DCD expression in heart and skeletal muscle. (A) Representative immunoblot and densitometric analysis of four independent experiments
to evaluate DCD protein levels in skeletal muscles or heart samples from SHAM, MI, PI, and PI + MI mice (*P, 0.05 vs. SHAM skeletal muscle; n ¼ 9
tissues/group). GAPDH protein levels did not significantly change among the samples. (B) DCD mRNA levels in skeletal muscles from SHAM, MI, PI, or
PI + MI (*P, 0.05 vs. SHAM; n ¼ 9 tissues/group). (C ) DCDmRNA levels in heart samples from SHAM, MI, PI, or PI + MI (not significant; n ¼ 9 tissues/
group).
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known. In addition, it has been demonstrated that humanDCD is phos-
phorylated at Tyr23 and polymethylated at Lys,34 further complicating
the possibility of associating an exact molecular mass to a specific
peptide form.
In summary, this study identifies a novel biochemical mechanism of
remote ‘crosstalk’ between skeletal muscle and the heart, based on the
molecular actions of a novel detrimental myokine, i.e. DCD. These re-
sults might explain, at least in part, the important association between
LE-PAD and cardiovascular mortality and morbidity.3,4 These results
might have important clinical implications in patients with diffuse vascu-
lar disease, since they suggest that treatment of peripheral artery dis-
ease, in addition to the amelioration of limb perfusion and function,
might also significantly improve cardiovascular outcome, as also sug-
gested by recent clinical observations.35 Thus, our data configure
DCD as a novel possible biomarker for LE-PAD and a novel exciting
therapeutic target to reduce heart failure development and progres-
sion in patients with diffuse vascular arterial disease.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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